Redeye provides an update on Scandinavian ChemoTech following the Q1 2025 report. Net sales came in 6% above our estimates, with strong order momentum continuing into Q2. In this update, we comment on the events during the quarter, including the separation of business areas and recent order announcements. As a result, we raise our estimates and fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/